A61K 31/566
Having an oxo group in position 17
Official title: having an oxo group in position 17, e.g. estrone
A61K31/566 (Having an oxo group in position 17) appears on 275 US grants and 524 published applications in this corpus.
Search patents in A61K- Granted patents
- 275
- Published applications
- 524
- Assignees
- 288
- Inventors
- 835
- Latest grant
- 1 Sep 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1976 | 1 | 0 |
| 1977 | 0 | 0 |
| 1978 | 0 | 0 |
| 1979 | 0 | 0 |
| 1980 | 0 | 0 |
| 1981 | 0 | 0 |
| 1982 | 0 | 0 |
| 1983 | 0 | 0 |
| 1984 | 0 | 0 |
| 1985 | 0 | 0 |
| 1986 | 0 | 0 |
| 1987 | 0 | 0 |
| 1988 | 0 | 0 |
| 1989 | 0 | 0 |
| 1990 | 0 | 0 |
| 1991 | 0 | 0 |
| 1992 | 0 | 0 |
| 1993 | 0 | 0 |
| 1994 | 0 | 0 |
| 1995 | 0 | 0 |
| 1996 | 10 | 0 |
| 1997 | 4 | 0 |
| 1998 | 18 | 0 |
| 1999 | 16 | 0 |
| 2000 | 4 | 0 |
| 2001 | 9 | 3 |
| 2002 | 4 | 12 |
| 2003 | 10 | 19 |
| 2004 | 2 | 26 |
| 2005 | 4 | 11 |
| 2006 | 4 | 11 |
| 2007 | 3 | 15 |
| 2008 | 6 | 14 |
| 2009 | 3 | 18 |
| 2010 | 4 | 15 |
| 2011 | 4 | 18 |
| 2012 | 6 | 16 |
| 2013 | 8 | 24 |
| 2014 | 10 | 28 |
| 2015 | 13 | 24 |
| 2016 | 15 | 28 |
| 2017 | 15 | 24 |
| 2018 | 8 | 22 |
| 2019 | 10 | 17 |
| 2020 | 13 | 26 |
| 2021 | 10 | 27 |
| 2022 | 13 | 31 |
| 2023 | 11 | 30 |
| 2024 | 15 | 22 |
| 2025 | 12 | 24 |
| 2026 | 10 | 19 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Anti-aging composition with mTOR inhibitor for humans and other mammals1 Sep 2026US 12,721,822 B2
- Dual chamber syringe for administering a hormone encapsulated by a hydrogel25 Aug 2026US 12,714,677 B2Vitalte Lifesciences Inc.
- Method of administering a hormone encapsulated by a hydrogel with a dual chamber syringe18 Aug 2026US 12,708,605 B2Vitalte Lifesciences Inc.
- Targeted measure of transcriptional activity related to hormone receptors31 Mar 2026US 12,590,335 B2Board of Regents, The University of Texas System
- 2-methoxyestradiol derivatives and medical uses thereof10 Mar 2026US 12,570,685 B2Institut Pasteur Korea
- Methods for the treatment of cancer using 1-(4-{[4-(dimethylamino)piperidin-1-yl]carbonyl}phenyl)-3-[4-(4,6-dimorpholin-4-yl-1,3,5-triazin-2-yl)phenyl]urea24 Sep 2026US 2026/0284068 A1Celcuity Inc.
- Methods for determining drug candidates20 Aug 2026US 2026/0245655 A1Mosaiques Diagnostics and Therapeutics AG
- Anti-her2 antibody-drug conjugate for treating breast cancer13 Aug 2026US 2026/0232833 A1Jiangsu Hengrui Pharmaceuticals Co., Ltd.
- Coadministration of estrogen with estrogen receptor modulator or degrader or er targeted protac for the treatment of estrogen responsive cancers23 Jul 2026US 2026/0207624 A1
- Pharmaceutical combination and use thereof16 Jul 2026US 2026/0199376 A1Ascentage Pharma Group Corp Limited
Most cited
By later US patents
- Estrogenic compounds as anti-angiogenic agents112US 5,504,074 AChildren's Medical Center Corporation · 1996
- Treatment of urinary incontinence with nitric oxide synthase substrates and/or nitric oxide donors alone or in combination with estrogen or progesterone and/or other agents91US 5,789,442 ASchering Corporation · 1998
- Regulation of estrus and ovulation in gilts82US 6,028,057 AThorn BioScience LLC · 2000
- Controlled release of steroids from sugar coatings80US 5,547,948 AAmerican Home Products Corporation · 1996
- Apparatus and method for delivering compounds to a living organism77US 6,471,979 B2Estrogen Vascular Technology, LLC · 2002